Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor Authors: Jakob Christoph Voran, Željka Radić, Lucia Sophie Kilian, Felix Braun, Christoph Röcken, Derk Frank, Hatim Seoudy Published: 2026 ABSTRACT AbstractBackgroundRare hereditary cardiac amyloidosis (CA) may mimic transthyretin or light-chain cardiomyopathy, and reports for effective therapy in these entities are limited.Case SummaryA 61-year-old man presented with progressive heart failure (NYHA functional class III). Medical history included bilateral carpal tunnel syndrome, chronic kidney disease, and family history notable for amyloidosis in his brother and suspected CA-related death in their mother. Cardiac magnetic resonance imaging showed late gadolinium enhancement consistent with CA, echocardiography increased left ventricular thickness and diastolic dysfunction. Light-chain CA was excluded. Genetic testing identified an Apolipoprotein A-I (ApoA1) mutation (p.L202P). ApoA1 amyloid was confirmed in a gastric biopsy. Therapy with dapagliflozin led to clinical improvement.DiscussionRecognition of ApoA1-associated CA relies on clinical history and genetic confirmation. Screening of first-degree relatives is advised. SGLT2-inhibitor therapy may improve symptoms, extrapolated from observational transthyretin-cardiomyopathy studies.Take-Home MessageRare hereditary CA represents an important differential diagnosis in CA cases. Sodium-glucose cotransporter 2 inhibitors may represent a treatment option.Key Words: cardiac magnetic resonance, cardiomyopathy, genetic disorders, phenotype History of Presentation A 61-year-old man presented with progressive dyspnea, fatigue (NYHA functional class III), and mild dysphonia. Vital signs showed an elevated blood pressure (RR 160/100, heart rate 68 beats/min) for timeline of the case see Table 1. Take-Home Messages •Consider hereditary amyloidosis such as AApoA1 in patients with familial patterns and other unusual presentations (systemic features, right-sided cardiac disease). Consider hereditary amyloidosis such as AApoA1 in patients with familial patterns and other unusual presentations (systemic features, right-sided cardiac disease). •Genetic testing confirms diagnosis, informs prognosis, and enables cascade screening of first-degree relatives. Genetic testing confirms diagnosis, informs prognosis, and enables cascade screening of first-degree relatives. •Therapy with SGLT2 inhibitors may improve symptoms even in rare hereditary cardiac amyloidosis. Therapy with SGLT2 inhibitors may improve symptoms even in rare hereditary cardiac amyloidosis. Table 1Timeline of the CaseDateEventsPast medical history61-year-old man with progressive dyspnea (NYHA functional class III) and mild dysphonia. History of carpal tunnel syndrome, chronic kidney disease.Prior diagnosticsElevated NT-proBNP, TTE: preserved ejection fraction, diastolic dysfunction, hypertrophy; CCTA: nonobstructive CAD; Fabry's disease was excluded.Key investigationsMRI: increased ventricular wall thickness, atrial septal hypertrophy, minimal pericardial effusion, inadequate myocardial nulling, and diffuse late gadolinium enhancement; Genetic testing: mutation in TTR-Gene excluded, c.605T>C of the APOA1 gene; Amyloid deposits immunoreactive for Apolipoprotein A-I antibodies in gastric biopsy.ManagementSGLT2 inhibitor therapy, Evaluation of liver transplantation, Genetic screening of first-degree relatives.9-mo follow-upImproved symptoms, NT-proBNP decreased, clinically stable.ApoA1 = Apolipoprotein A-I; CAD = coronary artery disease; CCTA = Coronary computed tomography angiography; MRI = magnetic resonance imaging; NT-proBNP = N-terminal pro–B-type natriuretic peptide; SGLT2 = Sodium-glucose cotransporter 2; TTE = transthoracic echocardiography. Timeline of the Case ApoA1 = Apolipoprotein A-I; CAD = coronary artery disease; CCTA = Coronary computed tomography angiography; MRI = magnetic resonance imaging; NT-proBNP = N-terminal pro–B-type natriuretic peptide; SGLT2 = Sodium-glucose cotransporter 2; TTE = transthoracic echocardiography. Past Medical History Before presentation, the patient had undergone several years of evaluation for his symptoms by his general practitioner, local nephrologists, and local cardiologists. His history included bilateral carpal tunnel syndrome (without surgical therapy) and chronic kidney disease (G3bA1, unclear etiology for the past 3 years). N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels increased over the past years. Transthoracic echocardiography showed elevated myocardial wall thickness with preserved EF and diastolic dysfunction. Exercise testing showed a reduced functional capacity without signs of ischemia on electrocardiogram (ECG). Stress echocardiography showed no cardiac wall motion abnormalities. Ultrasound of the carotid arteries revealed atherosclerosis without significant stenosis. As his older brother suffered from severe coronary artery disease and had undergone coronary artery bypass graft, coronary computed tomography angiography was done revealing nonobstructive coronary artery disease (coronary artery calcium score 79, Coronary Artery Disease-Reporting and Data System 1). A few years ago, Fabry's disease had been excluded by enzymatic testing. Family history was notable for amyloidosis in his brother (diagnosis confirmed a few days before presentation, with a mutation in Apolipoprotein A-I [ApoA1]) as well as death of his mother from suspected amyloid-related disease and heart failure. Medication at the point of presentation included aspirin 100 mg (once daily) and atorvastatin 20 mg (once daily). ApoA1-Associated Cardiac Amyloidosis AL = amyloid light-chain; ApoA1 = apolipoprotein A-I; ATTR = transthyretin amyloidosis; CAD = coronary artery disease; CKD = chronic kidney disease; CTS = carpal tunnel syndrome; HFpEF = heart failure with preserved ejection fraction; LGE = late gadolinium enhancement; LV = left ventricle; RV = right ventricle; SGLT2i = sodium-glucose cotransporter 2 inhibitor; TTR = transthyretin. Differential Diagnosis •Wild-type transthyretin amyloid (ATTR) amyloidosis/hereditary ATTR amyloidosis Wild-type transthyretin amyloid (ATTR) amyloidosis/hereditary ATTR amyloidosis •Light-chain amyloidosis Light-chain amyloidosis •Rare forms of cardiac amyloidosis including hereditary amyloidosis due to ApoA1 variants. Rare forms of cardiac amyloidosis including hereditary amyloidosis due to ApoA1 variants. •Hypertensive or hypertrophic cardiomyopathy Hypertensive or hypertrophic cardiomyopathy Investigations A 12-lead ECG showed normal sinus rhythm, with preterminal negative T waves. ECG did not show typical findings such as pseudoinfarction pattern or low QRS voltage. However, QRS voltage was disproportionately low in relation to the increased left ventricular wall thickness. Echocardiography revealed increased left ventricular and right ventricular wall thickness (end-diastolic interventricular septum thickness:17 mm; end-diastolic right ventricular free wall thickness: 10 mm) (Figure 1A), preserved ejection fraction (EF) (EF biplane 55%, 3-dimensional EF 52%), diastolic dysfunction (average E/E′ = 18), biatrial dilation, minimal pericardial effusion, valvular thickening, and moderate tricuspid regurgitation). Left ventricular global longitudinal strain did not show the characteristic apical sparing pattern (Figure 1B). Cardiac magnetic resonance imaging demonstrated increased left and right ventricular wall thickness, atrial septal hypertrophy, minimal pericardial effusion, inadequate myocardial nulling, and diffuse late gadolinium enhancement—consistent with cardiac amyloidosis (Figure 1C). Imaging Findings (A) Apical 4-chamber transthoracic echocardiogram with severe hypertrophy. (B) Left ventricular global longitudinal strain on transthoracic echocardiography. (C) Cardiac magnetic resonance imaging: Diffuse late gadolinium enhancement consistent with amyloid infiltration. Blood test showed an elevated NT-proBNP (1,210 pg/mL), which increased further to 1,580 pg/mL before therapy initiation. Serum/urine immunofixation was negative. Serum free light chains were slightly elevated (lambda 32 mg/L, kappa 33 mg/L) with a normal kappa/lambda ratio 1.04. High-density lipoprotein cholesterol was slightly decreased (0.68 mmol/L). Genetic testing with exon sequencing 1 to 4 of TTR-Gene (OMIM ∗176300) did not reveal changes compared with the reference sequence of the TTR-Gene (NM_00371.3). As at this timepoint the results of the genetic testing of his brother became known, a further genetic testing of the AApoA1 was ordered. Here the mutation c.605T>C of the APOA1 gene (NM_000039.3) was reported. This corresponds to a pathogenic ApoA1 mutation in exon 4 (p.L202P). As a consequence, the diagnosis of AApoA1 was made. For evaluation for liver transplantation and follow-up of a previously reported Helicobacter pylori infection of the stomach, gastroscopy was performed, and biopsies were obtained from a small ulcer in the gastric antrum. Amyloid deposits were identified in the lamina propria by polarization microscopy. Further histochemical analysis showed immunoreactivity for complement C9 and ApoA1 antibodies (Figure 2). Imaging Findings Top left: Hematoxylin-eosin (H&E), ×60 magnification. Top right: H&E, ×200 magnification. Middle left: Congo red fluorescence, ×60 magnification. Middle right: Congo red fluorescence, ×200 magnification. Bottom left: Anti-complement C9 antibody, ×200 magnification. Bottom right: Anti-apolipoprotein A1 antibody, ×200 magnification. Management Sodium-glucose cotransporter 2 (SGLT2) inhibitor (dapagliflozin) therapy was initiated. The patient was referred to hepatology for evaluation of potential liver transplantation. First-degree relatives underwent cascade genetic screening (results are not disclosed). Outcome and Follow-Up Symptoms substantially improved to NYHA functional class I (NT-proBNP: 804 ng/L). At 9 months’ follow-up, the patient remained clinically stable, with no heart failure hospitalizations and an uneventful course. Discussion AApoA1 is a rare hereditary systemic amyloidosis that can phenocopy ATTR cardiomyopathy. The mutation found (c.605T>C) relates to a change of the amino acid Leucin located in the N-terminal region of ApoA1 to the amino acid proline, a hotspot region for amyloidogenic mutations.1,2 In the Human Genome Variation database there was no entrance of the same mutation but a mutation on the same locus (c.605T>G).1 In ClinVar (Reference: RCV001699853) there are 2 reports with a classification as pathogenic (but with no further specification of associated disease).3 Key diagnostic clues include the following: 1.Systemic manifestations (bilateral carpal tunnel, dysphonia, kidney disease) Systemic manifestations (bilateral carpal tunnel, dysphonia, kidney disease) 2.Strong familial pattern with confirmed ApoA1 mutation Strong familial pattern with confirmed ApoA1 mutation 3.Proven immunoreactive amyloid deposits to ApoA1 antibodies Proven immunoreactive amyloid deposits to ApoA1 antibodies The disease typically follows an autosomal dominant inheritance pattern,4 making cascade screening of first-degree relatives important. Diagnosis requires exclusion of light-chain amyloidosis and multimodal imaging. Compared with light-chain, AApoA1 has a rather favorable prognosis (median survival >172 months).5 Although SGLT2 inhibitor therapy has been previously reported to be effective in ATTR cardiomyopathy,6,7 its use in AApoA1 is extrapolated but may improve symptomatic status. Liver transplantation remains a definitive therapy to decreased amyloid production.4 This case underscores the importance of recognizing rare hereditary forms in patients. Interestingly, the 2023 American College of Cardiology Expert Consensus Decision Pathway on Cardiac Amyloidosis8 list in particular inflammatory diseases as suggestive for rare causes including AApoA1 but neither this case nor other case reports mention any concomitant inflammatory diseases.1,4,5 In the 2021 statement of the European Society of Cardiology working group,9 clues on rare causes of amyloidosis are provided in more detail but advice on when to test for rare amyloid subtypes remains rather vague (European Society of Cardiology: concomitant kidney disease, American College of Cardiology: dialysis status and family history) in both statements.8,9 In light of costly specific therapy for ATTR amyloidosis, we see a need for more specific guidance (also implemented in flowcharts) for when to test for rare amyloidosis. Funding Support and Author Disclosures Dr Voran has received support by the clinician scientist program of the Medical Faculty of the Christian-Albrechts-University Kiel. Dr Seoudy has received speaker honoraria and travel support from Alnylam, AstraZeneca, Bayer, Boehringer-Ingelheim, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References